Picture a woman at her kitchen table at 2 a.m. The scale has moved. Her clothes fit differently. Everyone tells her she looks wonderful. She feels flat, frightened, or oddly grieving, and has no idea whom she could tell.
Now picture a man whose blood sugar has finally come down. His doctor is pleased. He has been called a success. He has not felt like himself for weeks, and nobody has asked.
Nursing teaches you that what people say first is rarely all of it. I have spent more than thirty years as a nurse. I am also someone who has struggled while taking a glucagon-like peptide-1 (GLP-1) medicine.
I started without doing what I would do for anyone else. I did not research it. Since then, I have learned that knowing what to do and being able to do it for yourself are different things.
Real physician voices, twice a week
Free, and one click to unsubscribe.
I have prediabetes, and five members of my family developed type 2 diabetes in later life. I understand why people want these medicines. I understand why they fear losing access.
I had low moods, anxiety, frustration, and moments of hopelessness while managing symptoms that kept changing. Gastric trouble made eating difficult. I felt lethargic and foggy. People told me to “just eat.” I wanted one normal meal without gastric upset. Just one thing I could eat comfortably.
My head had not caught up with what my eyes were seeing in the mirror. I did not recognize the woman looking back. I wondered what was happening to my relationship with food. I could not work it out alone.
Was my difficulty eating something I should discuss with an eating disorder specialist? I needed someone qualified to explore that with me.
Other users have spoken to me about anxiety, depression, and low mood. Some describe eating habits that worry them and wonder whether they are moving toward an eating disorder. They need assessment, including attention to physical symptoms and nutrition, and room to explain what has changed.
My daughter has anxiety. As her mother, I care deeply about what happens after someone asks for help. I want support to be available while they still have the courage and energy to seek it.
The research offers reassurance. In January 2026, the Food and Drug Administration reported a review of 91 placebo-controlled trials involving 107,910 people. It found no increased risk of suicidal thoughts or behavior, depression, or anxiety, and requested removal of the suicidality warning from affected U.S. labels.
That finding deserves to be heard. So do patients describing distress. My experience cannot establish what caused it. Symptoms, difficulty eating, changes in my body, and fear about treatment were happening together.
A 2026 JAMA Network Open interview study of 30 adults across 15 U.S. states described reduced food noise alongside adverse effects, stigma, and uneven clinical support. These interviews illuminate experiences; they cannot tell us how common those experiences are or establish medication causation.
I want us to ask what food meant to someone before treatment. If it offered comfort during anxiety, what helps them cope now? If they feel grief or uncertainty about a changing body, can they say so without feeling ungrateful? Those questions give a clinician somewhere to begin, without assuming a diagnosis or deciding in advance that the medicine must be responsible.
The scale of use makes this urgent. In November 2025, KFF reported that 18 percent of U.S. adults had used a GLP-1 medicine and 12 percent were currently using one. A 2024 Oxford Economics forecast projected around 40 million Americans using these medicines by 2030. That is a forecast, dependent on access and uptake, and says nothing about how many will experience psychological distress.
I read that figure and think about the person who cannot bring themselves to say they are struggling. Who will notice? Who will help if the referral is unaffordable?
Some support exists. Australia’s Better Access initiative provides mental health treatment rebates for eligible people. In the United States, the Medicare GLP-1 Bridge is widening medication access for eligible beneficiaries. As access expands, service planners should explain how patients will reach psychological care when needed.
I want mood, sleep, eating, and coping discussed before treatment and revisited during follow-up, including treatment changes and stopping. Appropriate screening should lead to clinical assessment and a clear plan. Online prescribing should carry the same expectation of accessible follow-up as an appointment in a consulting room.
For governments, insurers, and health departments, the questions are practical. Who funds the time to ask? Who pays when assessment identifies someone needing help? Can practices reach psychologists, dietitians, and eating disorder specialists? How long will patients wait, and who checks whether they receive care?
Fund clinician training, coordinated referrals, and affordable remote care where appropriate. Measure whether people reach support. A referral letter alone cannot tell us that.
Peer groups can offer companionship and language for experiences people struggle to explain. Administrators need training, current referral information, and a clear response to concerning posts. Members need to know when a group is monitored and where to seek urgent help directly.
At the next appointment, I would ask three questions.
- How are you feeling in yourself, including your mood and enjoyment of ordinary life?
- Has eating become difficult, frightening, or hard to manage?
- What support do you need, and how will we make sure you can reach it?
Silence is not safety. The evidence is reassuring about psychiatric risk overall. It cannot tell us everything about how an individual is coping. Whatever medicine someone takes, they deserve to be asked how they are and to know where to go if the answer is “not well.”
At follow-up, I would ask clinicians to make room for the part of the story a patient may struggle to tell. Ask about eating comfortably, managing work, and enjoying ordinary life. Explore physical symptoms, nutrition, and emotional distress together, including fears about continuing or stopping treatment.
Before the appointment ends, agree on the next step. Arrange further assessment or referral when needed, explain whom to contact if things worsen, and set a date to check back. I needed help making sense of what was happening to me. Follow-up should make that help easier to reach.
Patience C. Ennis is a registered nurse, author, Results Coach, glucagon-like peptide-1 (GLP-1) user, and the founder of Body Compass, an education and navigation platform for people living with, considering, or moving beyond GLP-1 treatment. A graduate of King’s College London, she draws on more than three decades of clinical experience across emergency, community, palliative, and aged care, bringing together clinical knowledge, lived experience, and patient education to address the questions that often sit beyond the prescription.
Through Body Compass, she develops evidence-informed resources, books, practical tools, news updates, and non-clinical coaching support designed to help people understand changing appetite, side effects, strength, food noise, treatment adaptation, maintenance, and stopping. Her work is grounded in clarity, dignity, and honest interpretation of evidence, without hype, shame, or false certainty. Her aim is not to tell people what to decide, but to help them understand the terrain, ask better questions, and navigate metabolic health with greater confidence in everyday life and care.
She is the author of When GLP-1 Feels Different: Plateau, Food Noise, Adaptation and the Fear of “Resistance” (2026), available on Amazon and through Body Compass. Her other titles include Living Well on GLP-1 Medication: A Practical Guide to Everyday Life Beyond the Prescription, The Body Compass 30-Day Navigation Diary: A Reflective Daily Companion for GLP-1 Treatment, and The 30-Day GLP-1 Navigation Companion: Observation, Reflection, Preparation, Navigation.
She shares updates on LinkedIn, Facebook, the Body Compass Facebook page, Instagram, X, TikTok, and YouTube.
Your KevinMD author page is one of the top results for your name. Turn it into a premium profile, publish in 1 to 3 days, and get a guaranteed podcast slot.

